Sumitomo Dainippon Reports Results of Lurasidone Hydrochloride (lurasidone) in P-III JEWEL Study in Patients with Schizophrenia

 Sumitomo Dainippon Reports Results of Lurasidone Hydrochloride (lurasidone) in P-III JEWEL Study in Patients with Schizophrenia

Sumitomo Dainippon’s Latuda (lurasidone HCl) Receives NMPA’s (CFDA) Approval for Schizophrenia

Shots:
  •  The P-III JEWEL Study involves assessing lurasidone (40 mg/day) vs PBO @6wks. in 483 patients with Schizophrenia, conducted for regulatory approval in Japan
  • The P-III JEWEL Study results demonstrated the patients treated with Lurasidone responded positively;
    PANSS (Positive and Negative Syndrome Scale) score (-19.3 vs -12.7); AE (47.0% vs 51.1%); patients discontinued treatment (19.4% vs 25.4%); patients discontinued treatment due to AE (5.7% vs 6.4%); well-tolerated
  •  Lurasidone is an atypical antipsychotic candidate indicated to treat Schizophrenia and is approved in multiple countries including the US & EU in 2010 & 2014 respectively. In H1’19, Sumitomo plans to file NDA for Lurasidone in Japan, for schizophrenia & bipolar depression

Click here to read full press release/ article | Ref: Ds-pharma | Image: Angelinipharma

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post